Periventricular gliomas: Evaluation of the risks associated with ventricular opening in two cohorts-one prospective with TachoSil® for ventricular sealing and the other without it retrospective
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.TachoSil® effectively seals the ventricles during glioma surgery, reducing complications and improving resection extent. This study suggests TachoSil® is safe and beneficial for patients undergoing ventricular opening for periventricular gliomas.
Area Of Science
- Neurosurgery
- Oncology
- Biomaterials
Background
- Ventricular opening (VO) in periventricular glioma surgery poses risks like leptomeningeal spread (LMS) and postoperative complications.
- No specific ventricular sealants are currently established, despite TachoSil®'s use in dural sealing.
Purpose Of The Study
- To evaluate the safety and effectiveness of TachoSil® as a ventricular sealant in periventricular gliomas with VO.
Main Methods
- A single-center observational study compared a prospective TachoSil® cohort (37 patients) with a retrospective control cohort (31 patients).
- Data collected included epidemiological, clinical, radiological, and surgical variables, focusing on VO-related complications (CSF leak, infection, hydrocephalus, LMS).
Main Results
- Patients receiving TachoSil® demonstrated wider tumor resections (1.54 cm³ vs. 3.71 cm³ residual volume, p=0.032).
- TachoSil® use was associated with significantly fewer VO-related postoperative complications (2 vs. 9 patients, p=0.008).
Conclusions
- TachoSil® is a safe and effective ventricular sealant for glioma surgery involving VO.
- It reduces VO-related complications, enhances resection extent, and lowers readmissions/reinterventions.
- A randomized clinical trial is recommended to further validate these findings.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.